Jardiance's CV Benefit: Can A Single Study Carry The Day At FDA?
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency finds support for cardiovascular mortality benefit with Boehringer/Lilly's diabetes drug, but advisory committee will review weaknesses in outcomes trial's component data.
You may also be interested in...
Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review
US FDA does not raise any major concerns about study’s design or results to support cardiovascular risk reduction claim for Novo Nordisk’s GLP-1 agonist liraglutide ahead of advisory committee, but agency gives close scrutiny to non-CV safety events of interest.
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
US labeling for Boehringer/Lilly's SGLT-2 inhibitor empagliflozin includes results from MACE primary endpoint and its individual components in the EMPA-REG trial, but indication statement is limited to CV risk reduction benefit.
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
Companies are supporting new US-labeled indication for cardiovascular mortality risk reduction with a consumer education campaign, direct-to-consumer advertising and cardiologist detailing.